Search company, investor...
Zymeworks company logo

Zymeworks

zymeworks.com

Founded Year

2004

Stage

IPO | IPO

Total Raised

$146.87M

Date of IPO

4/28/2017

Market Cap

1.30B

Revenue

$0000 

About Zymeworks

Zymeworks (NYSE: ZYME) (TSX: ZYME) is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of multifunctional biotherapeutics.

Headquarters Location

1385 West 8th Avenue Suite 540

Vancouver, British Columbia, V6H 3V9,

Canada

604-678-1388

Missing: Zymeworks's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Zymeworks's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Zymeworks

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Zymeworks is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

838 items

Zymeworks Patents

Zymeworks has filed 1 patent.

The 3 most popular patent topics include:

  • Monoclonal antibodies
  • Clusters of differentiation
  • Immunology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/12/2019

6/7/2022

Clusters of differentiation, Immune system, Immunology, Monoclonal antibodies, Transcription factors

Grant

Application Date

3/12/2019

Grant Date

6/7/2022

Title

Related Topics

Clusters of differentiation, Immune system, Immunology, Monoclonal antibodies, Transcription factors

Status

Grant

Latest Zymeworks News

Zymeworks Announces Abstract for Zanidatamab in Late-Line HER2-Positive Hormone-Receptor Positive (HR+) Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium (SABCS)

Nov 22, 2022

VANCOUVER, BC — Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the publication of an abstract highlighting new clinical data for zanidatamab, a HER2-targeted bispecific […] The post Zymeworks Announces Abstract for Zanidatamab in Late-Line HER2-Positive Hormone-Receptor Positive (HR+) Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium (SABCS) appeared first on Life Sciences British Columbia.

Zymeworks Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Zymeworks Rank

Zymeworks Frequently Asked Questions (FAQ)

  • When was Zymeworks founded?

    Zymeworks was founded in 2004.

  • Where is Zymeworks's headquarters?

    Zymeworks's headquarters is located at 1385 West 8th Avenue, Vancouver.

  • What is Zymeworks's latest funding round?

    Zymeworks's latest funding round is IPO.

  • How much did Zymeworks raise?

    Zymeworks raised a total of $146.87M.

  • Who are the investors of Zymeworks?

    Investors of Zymeworks include CTI Life Sciences Fund, Fonds de Solidarite FTQ, Eli Lilly and Company, Lumira Ventures, BDC Healthcare Venture Fund and 11 more.

  • Who are Zymeworks's competitors?

    Competitors of Zymeworks include Oligomerix, ADV Bioscience, PhaseBio Pharmaceuticals, Dyax, Mirna Therapeutics and 12 more.

Compare Zymeworks to Competitors

B
Bolder BioTechnology

Bolder BioTechnology, Inc. uses advanced protein engineering technologies to create human protein pharmaceuticals with enhanced therapeutic properties. Most protein pharmaceuticals are rapidly eliminated by the body, which limits their effectiveness and requires that they be administered by frequent, often daily, injection. The company's products are designed to last longer in the body, which aims to allow them to be administered less frequently, e.g., once per week to once per month, and maximizes their therapeutic benefits to patients. Company scientists combine protein structure/function information with targeted protein modification technologies to rationally design long-acting protein pharmaceuticals that, in many cases, are 10-100-fold more potent than competing products prepared using non-targeted protein modification technologies. Bolder BioTechnology has a robust pipeline of products in preclinical development, including products for the treatment of hematological and endocrine disorders, cancer and infectious disease. The company intend to commercialize these products independently and through strategic alliances with corporate partners.

S
Synaptic Research

Synaptic Research LLC is a biotechnology company which conducts research and develops products based on naturally-occurring large protein molecules. Specifically, the company engineers proteins derived from toxins which affect the synaptic junction. A well-known example of such a protein is the Botulinum Neurotoxin, or BoNT. This protein has qualities of targeting and persistence which make it an excellent candidate for further engineering and development of therapeutic and pharmaceutical products.

D
Dialectica srl

Dialectica offers Neural Stem Cell-based Systems and Assays for drug screening in neurodegenerative diseases. The mission of Dialectica is to add value to the link between research and pharmaceutical and biotechnology companies that are active in the discovery of therapeutics for brain diseases. Dialectica develops and optimize Neural Stem Cell-based Systems and Assays for drug screening in neurodegenerative diseases.

T
Trellis Bioscience

Trellis Bioscience provides health care products and services. The Company develops treatments for infectious diseases and oncology indications such as therapeutic antibody treatments.

P
Pi Proteomics

Pi Proteomics LLC manufactures custom and catalog peptides for academia, the biotechnology industry, antibody companies and the pharma industry.

A
Amrita Therapeutics

Amrita Therapeutics develops drugs that combat public health threats of the 21st century with fewer side-effects and at an cost. Amrita Therapeutics therapies and cures will treat cervical cancer, CNS disorders, HIV/AIDS, malaria and/or tuberculosis by designing the products of bacteria to defend the human body against more than one disease simultaneously, utilizing or interfering in multiple pathways or mechanisms.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.